Restored human albumin solution compared with standard albumin in decompensated cirrhosis
Compares a restored albumin solution with standard albumin in adults with decompensated cirrhosis.
Key facts
- Who runs it
- Azienda Ospedaliero-Universitaria Di Bologna IRCCS Istituto Di Ricerca E Di Cura A Carattere Scientifico
- Where
- Italy4 sites in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Safety and efficacy of a human albumin solution with restored structural profile in patients with decompensated cirrhosis
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 88 people, planned
- Started
- 1 Sept 2025
- Expected to end
- 31 Dec 2026
- Type of study
- Interventional
- Record updated
- 6 May 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with decompensated liver cirrhosis and fluid in the belly (ascites) who need long-term albumin treatment. It compares a new albumin solution (reHA) with the standard albumin solution.
- Age
- 18 to 85 years
- Sex
- All sexes can join.
- Disease stage
- Liver cirrhosis of any cause, with grade 2 or 3 ascites. People with grade 1 ascites can join if they take water pills (at least 200 mg/die of an antialdosteronic drug ± furosemide 25 mg/die).
- Earlier treatment
- No albumin infusion in the prior 2 weeks, except for fluid drainage (paracentesis), SBP or AKI-HRS. No antiviral treatment for viral hepatitis started in the last 6 months. No experimental drugs in the last 2 months.
Main reasons for not taking part
- Ongoing sudden complications of cirrhosis, or a TIPS shunt or Budd-Chiari syndrome.
- Active cancer, except liver cancer (hepatocellular carcinoma) within Milan criteria.
- Previous organ transplant.
- Ongoing drinking of more than 21 alcohol units per week.
- Severe kidney (stage IV or V), heart (NYHA III or IV) or lung (GOLD III or IV) disease; pregnancy or breast-feeding.
The registry criteria, word for word
Show all 2 criteriaShow less
Who can take part
- Diagnosis of liver cirrhosis of any etiology (based on clinical, laboratory, endoscopic and ultrasonographic features); • Patients with grade 2 and 3 ascites according to the criteria of the International Club of Ascites [88] and patients with grade 1 receiving diuretic treatment (at least 200 mg/die of an antialdosteronic drug ± furosemide 25 mg/die); • Patients of both sexes aged between 18 and 85 years; • Written and autonomous informed consent
Who cannot take part
- HA infusion in the prior 2 weeks except for paracentesis, spontaneous bacterial peritonitis (SBP) and acute kidney injury-hepatorenal syndrome (AKI-HRS); • Ongoing acute complications of cirrhosis; • Active malignancy except for hepatocellular carcinoma within Milan criteria; • Previous organ transplantation; • Trans jugular intrahepatic portosystemic shunt (TIPS) or Budd-Chiari syndrome; • Antiviral treatment for viral hepatitis started in the last 6 months; • Ongoing alcohol consumption with >21 alcohol U/week or an expected low adherence to protocol; • Chronic organic renal failure stage IV and V; • Chronic heart failure NYHA class III or IV; • Chronic obstructive pulmonary disease GOLD III or IV; • Life expectancy <6 months due to extrahepatic diseases; • Severe psychiatric disorders; • Known or suspected hypersensitivity to HA; • Pregnancy and breast-feeding; • Patients enrolled in other interventional clinical study for the treatment of complication of cirrhosis; • Use of experimental drugs for the last 2 months prior the inclusion in the present study • Hypersensitivity to albumin preparations or to any of the excipients; • Hypersensitivity to Glutathione or any component of the Glutathione solution; • Females of child-bearing potential are excluded unless they meet one of the following criteria: - Post-menopausal defined as no menses for 12 months without an alternative medical cause [89]. If post-menopausal for less than 12 months, a negative pregnancy test is required; - Surgical sterilization for more than one month duration and a negative pregnancy test (permanent sterilization methods include: hysterectomy, bilateral salpingectomy and bilateral oophorectomy) [89]; - Intrauterine device in combination with a secondary barrier (e.g. diaphragm, condom or spermicide) and a negative pregnancy test
This trial is currently available in Italy.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The primary aim is to assess the impact on effective albumin concentration and the safety of the administration of the reHA solution, as compared to the standard commercial HA solution in patients with decompensated cirrhosis having the indication to long-term albumin treatment
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- Safety and efficacy of a human albumin solution with restored structural profile in patients with decompensated cirrhosis
- Plain-language title
- Restored human albumin solution compared with standard albumin in decompensated cirrhosisGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 6 May 2026